Specifically, the TP53/KRAS co-mutation subgroup manifested an exclusive increase in the expression of PD-L1 and mutational burden in the lung adenocarcinoma database, which also implies ICIs preference (43, 44). The gene discussed is TP53; the disease is lung adenocarcinoma.